Scotiabank analyst Sung Ji Nam maintains $Exact Sciences (EXAS.US)$ with a buy rating, and maintains the target price at $70.
According to TipRanks data, the analyst has a success rate of 50.8% and a total average return of 0.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Exact Sciences (EXAS.US)$'s main analysts recently are as follows:
The firm's assessment of Exact Sciences was adjusted following the company's announcement of Q3 results that did not meet expectations, coupled with a reduction in FY24 forecasts due to underwhelming outcomes and various challenges anticipated in Q4. The subsequent 30% post-market decline in the stock is perceived as potentially more indicative of market sentiment (crowded long) and apprehensions regarding growth prospects, with the view that there is potential for recovery from this recent downturn.
The company's recent challenges are seen as short-lived, although the recent results have been recognized as not meeting high standards.
Exact Sciences' Q3 revenue did not meet expectations, and the company has reduced its guidance for the second half of the year due to multiple factors affecting its Cologuard product. Despite this, long-range plans for 2027 remain unchanged, and it is anticipated that growth will pick up in 2025. The current valuation is perceived as having support in the low $50 range, with the recent 30% decline in stock price being viewed as excessive.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
豐業銀行分析師Sung Ji Nam維持$精密科學 (EXAS.US)$買入評級，維持目標價70美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.8%，總平均回報率為0.2%。
此外，綜合報道，$精密科學 (EXAS.US)$近期主要分析師觀點如下：
在Exact Sciences公佈的第三季度業績未達到預期之後，該公司對Exact Sciences的評估進行了調整，同時由於業績不佳以及預計在第四季度面臨的各種挑戰，對24財年的預測進行了下調。該股隨後盤後下跌了30％，這可能更多地表明瞭市場情緒（多頭擁擠）和對增長前景的擔憂，因爲該股有可能從最近的低迷中復甦。
儘管最近的業績被認爲不符合高標準，但該公司最近的挑戰被認爲是短暫的。
Exact Sciences第三季度的收入未達到預期，由於影響其Cologuard產品的多種因素，該公司下調了下半年的預期。儘管如此，2027年的長期計劃保持不變，預計增長將在2025年回升。目前的估值被認爲在50美元的低位區間內有支撐，最近股價下跌30％被認爲是過度下跌的。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
